No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IDYA IDEAYA Biosciences
- 39.850
- +0.830+2.13%
Close Apr 24 16:00 ET
2.98BMarket Cap-20331P/E (TTM)
40.310High38.960Low1.37MVolume39.130Open39.020Pre Close54.71MTurnover1.85%Turnover RatioLossP/E (Static)74.76MShares47.73552wk High4.80P/B2.95BFloat Cap18.11252wk Low--Dividend TTM73.99MShs Float47.735Historical High--Div YieldTTM3.46%Amplitude2.950Historical Low39.941Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ETSOUTH SAN FRANCISCO, Calif., April 24, 20
Express News | IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for Ide397 Monotherapy in Mtap-Deletion Squamous Non-Small Cell Lung Cancer
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences Is Maintained at Buy by Citigroup
IDEAYA Biosciences Is Maintained at Buy by Citigroup
Comments
Despite a high cash burn, the significant 55% annual revenue growth of IDEAYA Biosciences is encouraging. The company's limited cash burn relative to market capitalisation suggests it should be able to fuel growth with minor dilution or borrowing. Cash burn thus shouldn't be a major concern.
We're Hopeful That IDEAYA Biosciences (NASDAQ:IDYA) Will Use Its Cash Wisely
NEWS!
$IDEAYA Biosciences(IDYA.US$ IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer
Another run soon?
$IDEAYA Biosciences(IDYA.US$@Alvinnnnnnn89@AmyNic@Ripper1986
starting to look good from a rookie persoe tive. Thanks in advance.
starting to look good from a rookie persoe tive. Thanks in advance.
2
Did you get in
$IDEAYA Biosciences(IDYA.US$@AmyNic@Ripper1986 great day. in at 18.3
Thanks to peeps pushing me to be better.
Thanks to peeps pushing me to be better.
3
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg